Anthropic Strengthens Regulatory Response with Pharma CEO Hire

Anthropic has appointed former Novartis CEO Vas Narasimhan as a member of its Long-Term Benefit Trust. This is seen as a strategic move that goes beyond simply securing a customer, aimed at proactively responding to the AI regulatory environment that is expected to intensify going forward.

Narasimhan is well-versed in the processes of major regulatory bodies such as the FDA and EMA, and his recruitment is seen as preparation for the possibility that AI systems will eventually follow strict regulatory pathways similar to drug approval.

It also suggests that Anthropic is focusing on biomedical fields such as protein design, drug development, and clinical reasoning. This shows the company's intent to have AI technology recognized for its real value in the strictly regulated healthcare field, beyond being just a general-purpose tool.

Ultimately, this is interpreted as an attempt to transplant the pharmaceutical industry's governance model for clinical safety and post-market monitoring into AI safety management systems.